The programme for Australia’s inaugural boutique medtech investment roundtable, AusMedtechInvest 2024, is packed and features speakers from leading investment firms ARCHIMED, Artesian, Brandon Capital, Main Sequence, OneVentures, and Tenmile, as well as investment pitch presentations from medtech executives.
The speaking programme for AusMedtechInvest 2024 is today announced, featuring an industry-led programme with thought-provoking keynotes and panel session with leading investors and business leaders.
Held during Australia’s ‘biggest week in medtech’, at the Adelaide Convention Centre on Tuesday 21 May, AusMedtechInvest 2024, provides a brand new forum to connect the investment community with investment-seeking innovators. Qualified investors invited to .
The half-day event will feature keynote presentations from Rowena Gray, Director, ARCHIMED, who will provide a keynote on how its investments have internationalised successfully; Dr Amandeep Hansra, Founder, Medical Angels, who will discuss the role of wholesale investors in Australia’s biotech community and partnering with angel investors; and Alex Romero, Analyst, Main Sequence Ventures, will deliver a keynote address on deep tech investing and its role in healthcare.
AusMedtechInvest will also feature a medtech investment insights and market intelligence panel session with leading investors, Sarah Meibusch, Partner, OneVentures, who will chair the panel, Dr Steve Burnell, Managing Director, Tenmile; Rohan Gray, VC Portfolio Manager, Artesian; Dr Chris Nave, Founding Partner & Managing Director, Brandon Capital; and Fredrik Nyberg, Managing Director, MedTech Innovator.
In addition, AusMedtechInvest 2024 features ten-minute presentations from ten Australasian medtech companies, spanning early- to late-stage, that are actively seeking investors or partners to support their funding and co-development. Presenting companies include: Cyban, Fusetec, OncoRes Medical, Vaxxas, and Wellumio. See a list of confirmed investees .
Investors and presenting investees will also receive access to the AusPartnering business matching system for confidential discussions in the networking lounge.
AusMedtechInvest builds on the success of AusBioInvest, AusBiotech’s flagship investment event, and its well-established investment attraction programme that for almost 15 years has helped empower Australian companies to be competitive on a global scale, while connecting Australian life sciences companies with international capital markets, and risk-tolerant investors with investment-seeking life science companies.
Investors who attend AusMedtechInvest 2024 can also access a free day pass and/or discounted registration to AusMedtech 2024, underway in Adelaide from 22-23 May.
